BMO Capital analyst Etzer Darout reiterated a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of $96.00.
Etzer Darout has given his Buy rating due to a combination of factors, primarily focusing on Merus’s promising clinical developments and strategic positioning. The company is advancing its lead clinical asset, petosemtamab, with significant updates expected in 2025. These updates include Phase 2 data for head and neck squamous cell carcinoma (HNSCC) and colorectal cancer, which are anticipated to drive value and investor confidence.
Additionally, Merus’s innovative antibody platform, which supports multiple early- and mid-stage clinical programs, adds to the company’s potential for growth. The recent FDA approval of Bizgenri for NRG1+ cancers and its partnership with Partner Therapeutics further bolster Merus’s commercial prospects. With a strong cash position and a strategic focus on advancing its pipeline, Merus is well-positioned for future success, justifying the Buy rating.
Darout covers the Healthcare sector, focusing on stocks such as Q32 Bio, Protagonist Therapeutics, and Jasper Therapeutics. According to TipRanks, Darout has an average return of 27.7% and a 50.64% success rate on recommended stocks.
In another report released today, Truist Financial also reiterated a Buy rating on the stock with a $88.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com